COMPASS Pathways (CMPS) Scheduled to Post Earnings on Wednesday

COMPASS Pathways (NASDAQ:CMPS) is scheduled to post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect COMPASS Pathways to post earnings of ($0.52) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

COMPASS Pathways Price Performance

Shares of CMPS traded up $0.13 during trading hours on Monday, reaching $8.66. The company had a trading volume of 82,111 shares, compared to its average volume of 660,753. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14. The firm has a 50 day simple moving average of $9.51 and a 200-day simple moving average of $8.51. COMPASS Pathways has a 12-month low of $5.01 and a 12-month high of $12.75. The company has a market capitalization of $536.40 million, a price-to-earnings ratio of -3.62 and a beta of 2.39.

Insider Transactions at COMPASS Pathways

In related news, major shareholder Ekaterina Malievskaia sold 25,750 shares of COMPASS Pathways stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the completion of the transaction, the insider now directly owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Ekaterina Malievskaia sold 25,750 shares of COMPASS Pathways stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the transaction, the insider now owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder George Jay Goldsmith sold 23,881 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the sale, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 140,601 shares of company stock worth $1,338,911. Company insiders own 4.25% of the company’s stock.

Wall Street Analysts Forecast Growth

CMPS has been the topic of a number of research reports. Morgan Stanley assumed coverage on COMPASS Pathways in a report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research note on Tuesday, April 30th. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research note on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.